PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
140 produits trouvés pour "PD-1/PD-L1"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Human PD-L1 inhibitor III
CAS :Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formule :C97H155N29O29SCouleur et forme :SolidMasse moléculaire :2223.54PD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formule :C23H20ClFN2O3Masse moléculaire :426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Formule :C64H92N20O19SMasse moléculaire :1476.65683Camrelizumab
CAS :Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Degré de pureté :95% - 98.6%Couleur et forme :LiquidMasse moléculaire :143.7 kDaPacmilimab
CAS :Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Degré de pureté :98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :153.3 kDaProlgolimab
CAS :Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Degré de pureté :>95%Couleur et forme :LiquidMasse moléculaire :146.28 kDaHuman membrane-bound PD-L1 polypeptide
CAS :Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Formule :C85H140N26O36SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :2134.24H-20
CAS :H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.Formule :C44H64N10O15Couleur et forme :SolidMasse moléculaire :973.037Asudemotide
CAS :Asudemotide is a bioactive chemical.Formule :C58H80N10O17Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1189.31Anti-PD-L1 Blocking Antibody (5I615)
Anti-PD-L1 Blocking Antibody (5I615) is a Rabbit IgG monoclonal antibody targeting Human PD-L1 Blocking.N-deacetylated BMS-202
CAS :N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.Formule :C23H27N3O2Degré de pureté :98.13% - 99.58%Couleur et forme :SolidMasse moléculaire :377.48BMS-1001
CAS :BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formule :C35H34N2O7Degré de pureté :98.43%Couleur et forme :SolidMasse moléculaire :594.7Ref: TM-T8470
1mg58,00€5mg124,00€1mL*10mM (DMSO)172,00€10mg177,00€25mg299,00€50mg424,00€100mg587,00€200mg792,00€BMS-1166
CAS :BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.Formule :C36H33ClN2O7Degré de pureté :99.22%Couleur et forme :SolidMasse moléculaire :641.11Ref: TM-T5697
1mg71,00€5mg146,00€1mL*10mM (DMSO)197,00€10mg213,00€25mg406,00€50mg602,00€100mg893,00€200mg1.198,00€Avelumab
CAS :Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.Degré de pureté :95% - 97.17% (SDS-PAGE)Couleur et forme :LiquidMasse moléculaire :143.8 kDaBMS-8
CAS :BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formule :C27H28BrNO3Degré de pureté :98.88%Couleur et forme :SolidMasse moléculaire :494.42Ref: TM-T26859
1mg37,00€5mg79,00€1mL*10mM (DMSO)86,00€10mg124,00€25mg222,00€50mg340,00€100mg505,00€200mg705,00€Pembrolizumab
CAS :Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.Degré de pureté :95% - 99.70%Couleur et forme :LiquidMasse moléculaire :149 kDaNivolumab
CAS :Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Degré de pureté :98% - 98%Couleur et forme :LiquidMasse moléculaire :143.62 kDaBMS-1166-n-piperidine-co-n-piperazine dihydrochloride
CAS :BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formule :C41H45Cl3N4O5Degré de pureté :98.94%Couleur et forme :SoildMasse moléculaire :780.18
